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Type 2 diabetesThe morbidity and mortality rates related to diabetes are constantly rising, as well as those for other
noncommunicable diseases. The epidemic is spreading throughout the world, in both low- and high-resource
countries. Prevention is a key aspect in the battle against the disease and obstetricians play a critical role in the
ﬁght. Prevention starts in utero—for the diabetic mother, her infant, and future generations. The postpartum
period should not be neglected because it provides another window of opportunity to address prevention.
Data on the prevention of type 2 diabetes among women diagnosed with gestational diabetes are discussed.
© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology andObstetrics. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes is a silent epidemic of increasing proportions, which
is coupled with risk factors such as increasing age, obesity, inadequate
nutrition, and a sedentary lifestyle [1]. It is one of the most important
chronic noncommunicable diseases alongwith cancer, and cardiovascu-
lar and respiratory diseases. The diabetes-related death toll was
3.4 million in 2004, and it will be the seventh cause of death in 2030
[2]. This holds true for both high- and low-resource countries [3], with
more than 80% of deaths associated with diabetes occurring in low-
and middle-income countries [4].
Urgent steps to stop this epidemic are overdue. Focus should be
given to detection and treatment of diabetes, in all its forms—keeping
in mind that the prevalence of gestational diabetes mellitus (GDM)
peaks at 15% − 25% in certain populations—and prevention, which
starts in utero [5], although the postpartum period is also crucial.
Among women diagnosed with GDM there is a higher risk of devel-
oping type 2 diabetes in the future. This riskwas the ﬁrst outcomemea-
sure used to deﬁne the hyperglycemia threshold in pregnancy, more
than 50 years ago [6]. The cumulative risk of type 2 diabetes after
GDM is wide ranging—from 2.5% to as high as 70% at follow-up ranging
from 6 weeks to 28 years after delivery [7]. Women with prior GDM
constitute a high-risk group, which make them candidates for inter-
ventions to reduce the prevalence of type 2 diabetes. This may be a
key component for the long-term well-being of women and their off-
spring—both as children and as adults [8]—as well as for future
generations, through in utero environmental modiﬁcation [9].eig Vall de Hebron 115, 08035
behalf of International Federation ofThe present review discusses the current data on available interven-
tions, and considers the further studies and policy implementations that
can be encouraged to reduce the incidence of type 2 diabetes in the
postpartum period.
2. What is the evidence base for interventions?
Numerous trials have shown the efﬁcacy of various interventions to
prevent type 2 diabetes in high-risk populations [10–13]. However, the
focus for these trials was high-risk patients identiﬁed according to
impaired fasting glucose (IFG) or impaired glucose tolerance (IGT).
There is limited—albeit generally positive—evidence of the efﬁcacy of
these interventions among other high-risk groups, including those
with prior GDM [14]. Available data support threemainmodalities of in-
tervention: breastfeeding, lifestyle modiﬁcation, and pharmacological
treatment [15].
2.1. Breastfeeding
In contrast to other interventions, breastfeeding has an advantage for
both the mother and child [16,17]. Several studies have shown
breastfeeding to be a risk modiﬁer that may be beneﬁcial in the preven-
tion of type 2 diabetes [18,19]. Breastfeeding duration and intensity are
also important, with exclusive breastfeedingmore important than partial
breastfeeding, and a suggested duration of at least 3–9 months [20–22].
2.2. Lifestyle modiﬁcation
Lifestyle modiﬁcation may include diet and nutritional counseling,
weight reduction, and physical activity. This may be delivered byGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
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internet—at various levels of intensity and oversight.
The largest trial on prevention of type 2 diabetes was conducted by
the Diabetes Prevention Program (DPP). In that study [23], 3234 pa-
tients at high risk for diabetes were randomized to a standard care
group versus two possible interventions groups—lifestyle modiﬁcations
and metformin—with an approximately three-year follow-up. Impor-
tantly, the initial inclusion deﬁnition for diabetes risk was based on
IFG and IGT. Results from the study demonstrated that lifestyle modiﬁ-
cationwas signiﬁcantlymore potent in preventing type 2 diabetes com-
paredwithmetformin, with risk reduction at 58% and 31%, respectively.
Similar trends have been demonstrated by other randomized trials
[24–26].
In an ancillary analysis of theDPP trial [27], the focuswas on the sub-
group of women with prior GDM as the risk-deﬁning parameter, along
with the initial risk of IFG/IGT. Overall, 350 women with prior GDM
were included and were compared with 416 women with a prior live
birth without GDM. Results of the study demonstrated that there was
an approximately 70% risk of developing type 2 diabetes among the
women with prior GDM who were randomized to the control group;
and that among thosewith a history of GDM, both lifestylemodiﬁcation
and metformin achieved a risk reduction of approximately 50%
compared with the control group.
In another trial, Pérez-Ferre at al. [28] randomized 237 women with
prior GDM into two groups: Mediterranean diet as a lifestyle interven-
tion, including monitored physical activity, compared with a conven-
tional follow-up group. The study demonstrated a risk reduction of
approximately 25% for the lifestyle intervention group.
Although this risk reduction has not been consistent in all studies
[29], lifestyle modiﬁcations have been shown to be cost-effective and
cost saving [30].
2.3. Pharmacological treatment
As mentioned previously, the DPP study demonstrated the efﬁcacy
of metformin in reducing the progression to type 2 diabetes among
women with prior GDM [27].To date, it is still the largest study that
has shown a pharmacological intervention that effectively reduces the
risk of diabetes among women with prior GDM.
In smaller trials, other medications have also been tested
(troglitazone, pioglitazone, and acarbose). Buchanan et al. [31] studied
the effect of troglitazone versus placebo among 266 Hispanic women
with prior GDM. The study concluded that treatment signiﬁcantly re-
duced the rate of postpartum type 2 diabetes by approximately 45%.
However, troglitazonewaswithdrawn fromproduction because of hep-
atotoxicity. In an observational follow-up study of the same population
[32], pioglitazonewas given for three years to 89women. Similarly, this
was also shown to be effective in lowering progression rates to type 2
diabetes via an insulin-sensitizing effect and preservation of the func-
tionality of beta cells.
Acarbose has also been studied for type 2 diabetes prevention [26];
however, the study population was not selected for prior GDM as a
risk factor and instead IGT was the selected inclusion criteria. In the
study, 1429 patients were randomized to placebo or acarbose groups.
The results demonstrated a 25% risk reduction in progression to type 2
diabetes in the acarbose group (relative hazard 0.75; 95% CI, 0.63–0.90).
3. Are these interventions being implemented?
Aside from questions surrounding the efﬁcacy of possible interven-
tions, the cardinal issue is that of implementation. Being aware of the
risk, the possible interventions, and knowing their efﬁcacy is not always
enough [33,34]. Multiple organizations have published recommenda-
tions on postpartum follow-up and care of women with prior GDM,
most of which include recommendations on postpartum diabetesscreening but with only vague suggestions as to referral for preventive
therapy [35–37].
Adherence to these guidelines is insufﬁcient and the percentage of
women screened with any assessment for glycemic status ranges from
18% to 67% [15]. Nonadherence to these recommendations implies
that many physicians and women do not understand the increased
risk for type 2 diabetes. Although there are no studies that have properly
evaluated this, we can safely assume that if screening guidelines are not
being met then neither are preventive measures.
A postpartum continuum of prenatal care for women with GDM
marks a critical missed opportunity for research, clinical practice and
policy statements [38]. Parameters that may block implementation of
screening and preventive efforts, that therefore need to be addressed,
include tiredness and fatigue, childcare duties and lack of access to
childcare services, work commitments, psychosocial barriers, lack of en-
vironmental support, cultural barriers, lack of motivation, and ﬁnancial
and time constraints.
4. Conclusion
Type 2 diabetes can be reduced among populations at high risk,
including among women who have previously been diagnosed with
GDM. Future studies should focus on this speciﬁc population of
women, with or without IFG/IGT and other concomitant risk factors
such obesity, and family history. Guidelines for screening should be bet-
ter employed, aswell as providing encouragement to adopt appropriate
preventive measures. A comprehensive approach to diabetes preven-
tion should include provision of lifestyle interventions, breastfeeding
support, and appropriate pharmacological treatment. The most impor-
tant issue is not to abandon the diabetic pregnant woman once she
has delivered, but to continue care and follow-up for her and her
children’s future health.
The FIGO GDM initiative seeks to produce, disseminate, and imple-
ment evidence-based standards of care protocols for womenwith GDM.
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